Insider Buying: Achieve Life Sciences, Inc. (NASDAQ:ACHV) CFO Purchases 10,000 Shares of Stock

Achieve Life Sciences, Inc. (NASDAQ:ACHV) CFO Mark K. Oki bought 10,000 shares of the company’s stock in a transaction on Monday, March 17th. The stock was bought at an average price of $2.89 per share, for a total transaction of $28,900.00. Following the completion of the purchase, the chief financial officer now directly owns 10,000 shares in the company, valued at approximately $28,900. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

Achieve Life Sciences Trading Down 4.0 %

Shares of NASDAQ ACHV traded down $0.11 during trading hours on Wednesday, reaching $2.67. The stock had a trading volume of 144,656 shares, compared to its average volume of 168,573. Achieve Life Sciences, Inc. has a 52-week low of $2.51 and a 52-week high of $5.59. The firm has a market cap of $92.61 million, a price-to-earnings ratio of -2.36 and a beta of 1.67. The business’s fifty day moving average price is $3.13 and its two-hundred day moving average price is $3.98. The company has a current ratio of 6.78, a quick ratio of 6.78 and a debt-to-equity ratio of 0.31.

Achieve Life Sciences (NASDAQ:ACHV) last posted its quarterly earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.06). Analysts expect that Achieve Life Sciences, Inc. will post -1.17 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in ACHV. Geode Capital Management LLC lifted its position in shares of Achieve Life Sciences by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 755,845 shares of the biopharmaceutical company’s stock valued at $2,661,000 after buying an additional 6,736 shares during the last quarter. State Street Corp raised its stake in shares of Achieve Life Sciences by 6.8% during the 3rd quarter. State Street Corp now owns 431,520 shares of the biopharmaceutical company’s stock worth $2,045,000 after acquiring an additional 27,419 shares in the last quarter. Northern Trust Corp lifted its position in Achieve Life Sciences by 11.7% during the fourth quarter. Northern Trust Corp now owns 416,796 shares of the biopharmaceutical company’s stock valued at $1,467,000 after acquiring an additional 43,682 shares during the last quarter. LPL Financial LLC lifted its position in Achieve Life Sciences by 2.9% during the fourth quarter. LPL Financial LLC now owns 196,833 shares of the biopharmaceutical company’s stock valued at $693,000 after acquiring an additional 5,500 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Achieve Life Sciences in the fourth quarter valued at approximately $554,000. 33.52% of the stock is owned by institutional investors.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.